BTRX 246040
Alternative Names: BTRX-246040; LY 2940094Latest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Neumora Therapeutics
- Class Antidepressants; Antiparkinsonians; Drug withdrawal therapies; Small molecules
- Mechanism of Action Nociceptin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder; Parkinson's disease
- Discontinued Alcoholism
Most Recent Events
- 22 Jul 2022 No development reported - Phase-II for Major depressive disorder in USA (PO)
- 22 Jul 2022 No development reported - Phase-II for Parkinson's disease in USA (PO)
- 12 Oct 2021 BlackThorn Therapeutics has been acquired and merged into Neumora Therapeutics